Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes

Aggregation of misfolded proteins is characteristic of a number of neurodegenerative diseases, including Huntington disease (HD). The CCT/TRiC (chaperonin containing TCP-1/TCP-1 ring) chaperonin complex can inhibit aggregation and cellular toxicity induced by expanded repeat Huntingtin (mHtt) fragments. The substrate-binding apical domain of CCT/TRiC subunit CCT1, ApiCCT1, is sufficient to inhibit aggregation of expanded repeat mHtt fragments in vitro, providing therapeutic promise for HD. However, a key hurdle in considering ApiCCT1 as a potential treatment is in delivery. Because ApiCCT1 has a region of similarity to the HIV Tat protein cell-transduction domain, we tested whether recombinant ApiCCT1 (ApiCCT1r) protein could enter cells following exogenous delivery and modulate an established panel of mHtt-mediated cell-based phenotypes. Cell fractionation studies demonstrate that exogenous ApiCCT1r can penetrate cell membranes and can localize to the nucleus, consistent with a strategy that can target both cytosolic and nuclear pathogenic events in HD. ApiCCT1r application does indeed modulate HD cellular phenotypes by decreasing formation of visible inclusions, fibrillar oligomers, and insoluble mHtt derived from expression of a truncated mHtt exon 1 fragment. ApiCCT1r also delays the onset of inclusion body formation as visualized via live imaging. ApiCCT1r reduces mHtt-mediated toxicity in immortalized striatal cells derived from full-length knock-in HD mice, suggesting that therapeutic benefit may extend beyond effects on aggregation. These studies provide the basis for a potentially robust and unique therapeutic strategy to target mHtt-mediated protein pathogenesis.

[1]  X. Pu,et al.  DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats , 2012, Brain Research Bulletin.

[2]  S. Finkbeiner,et al.  Methylene Blue Modulates Huntingtin Aggregation Intermediates and Is Protective in Huntington's Disease Models , 2012, The Journal of Neuroscience.

[3]  Vladimir P Torchilin,et al.  Cell-penetrating peptides: breaking through to the other side. , 2012, Trends in molecular medicine.

[4]  J. Frydman,et al.  Cellular strategies of protein quality control. , 2011, Cold Spring Harbor perspectives in biology.

[5]  L. Crawford,et al.  Methods for measuring proteasome activity: current limitations and future developments. , 2010, Leukemia research.

[6]  Richard I. Morimoto,et al.  Chaperone networks: Tipping the balance in protein folding diseases , 2010, Neurobiology of Disease.

[7]  Leslie M Thompson,et al.  Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo* , 2010, The Journal of Biological Chemistry.

[8]  Judith Frydman,et al.  The Chaperonin TRIC Blocks a Huntingtin Sequence Element that promotes the Conformational Switch to Aggregation , 2009, Nature Structural &Molecular Biology.

[9]  Andrew D. Steele,et al.  Loss of Hsp70 Exacerbates Pathogenesis But Not Levels of Fibrillar Aggregates in a Mouse Model of Huntington's Disease , 2009, The Journal of Neuroscience.

[10]  Danielle A. Simmons,et al.  CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice , 2008, Molecular and Cellular Neuroscience.

[11]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[12]  G. Bates,et al.  Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease , 2007, Journal of neurochemistry.

[13]  Kazuyuki Takata,et al.  PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson’s disease rat model , 2006, Neurobiology of Disease.

[14]  Hiroshi Kimura,et al.  Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state , 2006, Nature Cell Biology.

[15]  J. Frydman,et al.  The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions , 2006, Nature Cell Biology.

[16]  F. Hartl,et al.  Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. , 2006, Molecular cell.

[17]  Y. Fujiki,et al.  Shuttling Mechanism of Peroxisome Targeting Signal Type 1 Receptor Pex5: ATP-Independent Import and ATP-Dependent Export , 2005, Molecular and Cellular Biology.

[18]  J. Olson,et al.  Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. , 2005, Human molecular genetics.

[19]  Hiroyuki Ogata,et al.  Metagrowth: a new resource for the building of metabolic hypotheses in microbiology , 2004, Nucleic Acids Res..

[20]  Judith Frydman,et al.  Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets. , 2004, Trends in cell biology.

[21]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[22]  Burkhard Rost,et al.  The PredictProtein server , 2003, Nucleic Acids Res..

[23]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Wetzel,et al.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human molecular genetics.

[25]  H. Zoghbi,et al.  Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. , 2001, Human molecular genetics.

[26]  M. MacDonald,et al.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.

[27]  E. Wanker,et al.  Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Ü. Langel,et al.  Cell-Penetrating Peptides , 2000, Methods in Molecular Biology.

[29]  H. Paulson,et al.  Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.

[30]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[31]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[32]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[33]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[34]  Priscille Brodin,et al.  A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.

[35]  A. Prochiantz,et al.  Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.

[36]  F. Hartl,et al.  Protein folding in the central cavity of the GroEL–GroES chaperonin complex , 1996, Nature.

[37]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[38]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[39]  Brian J Cummings,et al.  Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. , 2012, Journal of Huntington's disease.

[40]  P. Muchowski,et al.  Modulation of neurodegeneration by molecular chaperones , 2005, Nature Reviews Neuroscience.

[41]  Burkhard Rost,et al.  The PredictProtein server , 2003, Nucleic Acids Res..

[42]  K. Smetana,et al.  ISOLATION OF NUCLEOLI. , 1963 .